Technical Analysis for ZYNE - Zynerba Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 8.61 6.96% 0.56
ZYNE closed up 6.96 percent on Monday, October 21, 2019, on 87 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical ZYNE trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Weak + Overbought Other 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Bollinger Band Squeeze Range Contraction 6.96%
Weak + Overbought Other 6.96%
BB Squeeze + Upper Band Touch Range Contraction 6.96%

Older signals for ZYNE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company has two product candidates, including ZYN002 and ZYN001, which represent cannabinoid therapeutics for several indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In preclinical animal studies, ZYN002's permeation enhancer increased delivery of CBD through the layers of the skin and into the circulatory system. ZYN001 is a pro-drug of delta-9-tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. In preclinical animal studies, ZYN001 demonstrated effective skin permeation with sustained delivery and rapid conversion of ZYN001 to THC.
Pharmaceutical Pain Drugs Chemical Compounds Osteoarthritis Psychoactive Drugs Entheogens Fibromyalgia Cannabidiol Cannabinoids Fragile X Syndrome
Is ZYNE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 5 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 16.47
52 Week Low 2.75
Average Volume 801,919
200-Day Moving Average 9.2526
50-Day Moving Average 9.6422
20-Day Moving Average 7.769
10-Day Moving Average 7.881
Average True Range 0.6108
ADX 27.66
+DI 21.0962
-DI 21.9442
Chandelier Exit (Long, 3 ATRs ) 6.9976
Chandelier Exit (Short, 3 ATRs ) 8.6624
Upper Bollinger Band 8.3936
Lower Bollinger Band 7.1444
Percent B (%b) 1.17
BandWidth 16.079289
MACD Line -0.4103
MACD Signal Line -0.6345
MACD Histogram 0.2242
Fundamentals Value
Market Cap 114.14 Million
Num Shares 13.3 Million
EPS -2.60
Price-to-Earnings (P/E) Ratio -3.31
Price-to-Sales 0.00
Price-to-Book 1.77
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.75
Resistance 3 (R3) 9.70 9.26 9.56
Resistance 2 (R2) 9.26 8.97 9.29 9.50
Resistance 1 (R1) 8.94 8.79 9.10 8.99 9.43
Pivot Point 8.50 8.50 8.59 8.53 8.50
Support 1 (S1) 8.18 8.21 8.34 8.23 7.79
Support 2 (S2) 7.74 8.03 7.77 7.72
Support 3 (S3) 7.42 7.74 7.66
Support 4 (S4) 7.47